Novoteris LLC
🇺🇸United States
Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients
Phase 2
Terminated
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Nitric Oxide 160 ppm
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Novoteris, LLC
- Target Recruit Count
- 49
- Registration Number
- NCT02498535
- Locations
- 🇺🇸
University of Washington Medical Center (Site No. 100), Seattle, Washington, United States
🇺🇸Medical College of Wisconsin (Site No. 400), Milwaukee, Wisconsin, United States
🇺🇸* Entire USA* The sponsor will provide air transportation and housing to patients that are not located in the area of clinical trial sites. All trial sites can treat adults., Garden Grove, California, United States
© Copyright 2025. All Rights Reserved by MedPath